Panacea Biotec (BOM:531349) EBITDA: ₹317 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531349 Panacea Biotec Ltd BOM:531349
54 GF Score
Price ₹538.20
GF Value ₹359.92
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Panacea Biotec EBITDA?

Panacea Biotec BOM:531349 +0.09% 54 EBITDA is ₹317 Mil as of Mar. 2026. GuruFocus rates BOM:531349 with a GF Score™ of 54/100 and a GF Value™ of ₹359.92 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Panacea Biotec's EBITDA for the three months ended in Mar. 2026 was ₹78 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹317 Mil.

During the past 12 months, the average EBITDA Growth Rate of Panacea Biotec was 3.30% per year. During the past 3 years, the average EBITDA Growth Rate was -17.10% per year. During the past 5 years, the average EBITDA Growth Rate was -39.00% per year. During the past 10 years, the average EBITDA Growth Rate was -12.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Panacea Biotec was 107.00% per year. The lowest was -73.60% per year. And the median was -1.70% per year.

Panacea Biotec's EBITDA per Share for the three months ended in Mar. 2026 was ₹1.21. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹5.11.

During the past 12 months, the average EBITDA per Share Growth Rate of Panacea Biotec was 3.40% per year. During the past 3 years, the average EBITDA per Share Growth Rate was -17.00% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -39.00% per year. During the past 10 years, the average EBITDA per Share Growth Rate was -12.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Panacea Biotec was 107.00% per year. The lowest was -73.60% per year. And the median was -1.70% per year.

Panacea Biotec  (BOM:531349) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Panacea Biotec EBITDA Related Terms


Panacea Biotec EBITDA Historical Data

* Premium members only.

The historical data trend for Panacea Biotec's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panacea Biotec EBITDA Chart

Panacea Biotec Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16,729.70 557.31 408.61 307.40 317.40

Panacea Biotec Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 94.20 158.10 -86.90 167.90 78.30

BOM:531349 vs VRTX, REGN, ALNY: EBITDA Comparison

For the Biotechnology subindustry, Panacea Biotec's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Biotec EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panacea Biotec's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Panacea Biotec's EV-to-EBITDA falls into.


BOM:531349
54GF Score
Panacea Biotec Ltd BOM:531349
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Panacea Biotec's EBITDA for the fiscal year that ended in Mar. 2026 is calculated as

Panacea Biotec's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Mar. 2026, Panacea Biotec's EBITDA was ₹317 Mil.

Panacea Biotec's EBITDA for the quarter that ended in Mar. 2026 is calculated as

Panacea Biotec's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Mar. 2026, Panacea Biotec's EBITDA was ₹78 Mil.

EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹317 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of ₹317 Mil mean?
Panacea Biotec (BOM:531349) has a EBITDA of ₹317 Mil as of Mar. 2026. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Panacea Biotec.
Is Panacea Biotec's EBITDA too high?
Panacea Biotec's current EBITDA is ₹317 Mil. Overall, Panacea Biotec has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Panacea Biotec's EBITDA compare to VRTX and REGN?
Panacea Biotec's EBITDA of ₹317 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Biotechnology company?
A good EBITDA depends on the Biotechnology industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Panacea Biotec. Panacea Biotec's current EBITDA is ₹317 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Biotec stock overvalued right now?
Based on GuruFocus' analysis, Panacea Biotec (BOM:531349) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹359.92, compared to a current price of ₹538.20 — trading 49.5% above its estimated fair value. The current EBITDA is ₹317 Mil. Panacea Biotec's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Panacea Biotec (BOM:531349), the current EBITDA is ₹317 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Panacea Biotec (BOM:531349) Overvalued in 2026?

Based on GuruFocus' analysis, Panacea Biotec stock appears to be overvalued. The current stock price of ₹538.20 is trading 49.5% above its estimated GF Value™ of ₹359.92. GuruFocus considers Panacea Biotec to be Significantly Overvalued.

Key valuation signals for BOM:531349:

  • EBITDA: ₹317 Mil
  • GF Value™: ₹359.92 vs. price of ₹538.20 (49.5% above fair value)
  • GF Score™: 54/100 with 3 warning signs

No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Panacea Biotec Business Description

Other Exchanges PANACEABIO:India
Address Mathura Road, B-1 Extension/G-3, Mohan Co-operative Industrial Estate, New Delhi, IND, 110044
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
54GF Score

Get the complete analysis for BOM:531349

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹538.20
Price
₹359.92
GF Value